Compare MGY & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGY | WGS |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Oil & Gas Production | Retail: Computer Software & Peripheral Equipment |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 2.6B |
| IPO Year | 2017 | N/A |
| Metric | MGY | WGS |
|---|---|---|
| Price | $30.22 | $70.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | $28.17 | ★ $140.71 |
| AVG Volume (30 Days) | ★ 2.9M | 694.3K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $1,311,845,000.00 | N/A |
| Revenue This Year | $0.70 | $29.98 |
| Revenue Next Year | $9.46 | $24.85 |
| P/E Ratio | ★ $125.90 | $1,251.58 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.09 | $55.17 |
| 52 Week High | $30.44 | $170.87 |
| Indicator | MGY | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 72.24 | 34.67 |
| Support Level | $22.71 | $68.55 |
| Resistance Level | N/A | $76.21 |
| Average True Range (ATR) | 0.82 | 5.43 |
| MACD | 0.03 | -0.20 |
| Stochastic Oscillator | 92.95 | 7.04 |
Magnolia Oil & Gas Corp is an independent oil and natural gas company engaged in the acquisition, development, exploration, and production of oil, natural gas, and natural gas liquids (NGL) reserves. The company's oil and natural gas properties are located in Karnes County and the Giddings area of South Texas, where it targets the Eagle Ford Shale and Austin Chalk formations. It focuses on generating value for shareholders by delivering steady, moderate annual production growth resulting from its capital spending philosophy. The company operates in only one segment and derives the majority of its revenue from the sale of crude oil, natural gas, and natural gas liquids (NGLs).
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.